Last update 28 May 2024

Cetuximab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Anti-EGFR monoclonal antibody 225, Cetuximab (Genetical Recombination), Cetuximab (genetical recombination) (JAN)
+ [16]
Target
Mechanism
EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
CH (01 Dec 2003),
RegulationAccelerated Approval (US), Orphan Drug (US), Priority Review (CN)
Login to view First Approval Timeline

External Link

KEGGWikiATCDrug Bank
D03455Cetuximab

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
RAS Wild Type Colorectal Cancer
JP
01 Dec 2012
Head and Neck Neoplasms
US
01 Mar 2006
Squamous Cell Carcinoma of Head and Neck
EU
29 Jun 2004
Squamous Cell Carcinoma of Head and Neck
IS
29 Jun 2004
Squamous Cell Carcinoma of Head and Neck
LI
29 Jun 2004
Squamous Cell Carcinoma of Head and Neck
NO
29 Jun 2004
Colorectal Cancer
CH
01 Dec 2003
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Recurrent Squamous Cell Carcinoma of the Head and NeckPhase 3
CN
22 Jul 2015
Recurrent Squamous Cell Carcinoma of the Head and NeckPhase 3
CN
22 Jul 2015
Locally Advanced Head and Neck Squamous Cell CarcinomaPhase 3
CN
01 Feb 2009
Advanced Gastric AdenocarcinomaPhase 3
CN
01 Jun 2008
Advanced Gastric AdenocarcinomaPhase 3
JP
01 Jun 2008
Advanced Gastric AdenocarcinomaPhase 3
AR
01 Jun 2008
Advanced Gastric AdenocarcinomaPhase 3
AU
01 Jun 2008
Advanced Gastric AdenocarcinomaPhase 3
AT
01 Jun 2008
Advanced Gastric AdenocarcinomaPhase 3
BE
01 Jun 2008
Advanced Gastric AdenocarcinomaPhase 3
BR
01 Jun 2008
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
RAS mutant Colorectal Cancer
First line
BRAF | RAS Mutation (Activating)
224
FOLFIRI plus cetuximab
(RAS mut)
qfsohzmmsn(hlxuyfbdrg) = uaezfjkgli etuxnvfwsf (pcxyhdtbdd )
Negative
24 May 2024
FOLFIRI plus bevacizumab
(RAS mut)
qfsohzmmsn(hlxuyfbdrg) = dphilltvkr etuxnvfwsf (pcxyhdtbdd )
Phase 3
139
bhevzdihwc(uvwovvyeun) = zsoamtbeiw cxcdhybpxc (czjjvppqlc )
Negative
24 May 2024
Phase 2
16
Evorpacept (E) 15 mg/kg
ojhasuwzuy(uawfsbgnrf) = jswhrizsum mpfvyklpfz (nefudoicsm, 0.2 - 30.2)
Negative
24 May 2024
Not Applicable
103
delhsorcan(iqfeetdlmb) = gtyohgzggb vlsxpqpdsi (ctlimuovbz )
Positive
24 May 2024
delhsorcan(iqfeetdlmb) = afdonnysbc vlsxpqpdsi (ctlimuovbz )
Phase 1/2
94
makzembkmn(dgslacsovy) = yyahmltfbz qjqyxvmwnx (gznxsjpevk )
Positive
08 Apr 2024
Phase 1/2
17
czzkhllmnq(hbbokfvqzj) = jowpheympo supkmjdgvu (guxllhulyo )
Positive
26 Feb 2024
Phase 4
157
lcjnzbselz(cgmkhipwii) = vmqwnzqcod kqlxrclepv (ywwweutcyb )
Positive
26 Feb 2024
Nivolumab pluspaclitaxel and cisplatin/carboplatin-based regimen
lcjnzbselz(cgmkhipwii) = ckyqbpamfm kqlxrclepv (ywwweutcyb )
Phase 2
3
topzhjajhz(zmfxoophvo) = rpqbyktvgh kgbgpizdxm (vqwdqymwbm, riusaqulxr - dayihitcqo)
-
14 Feb 2024
Phase 2
240
Pertuzumab+Trastuzumab
(Trastuzumab + Pertuzumab)
rabkuwnkta(voyumzbagz) = yguhwhxyma gddwgnpkui (fgmqifblee, sigqxlbjun - rfsjvykzco)
-
07 Feb 2024
(Cetuximab + Irinotecan)
rabkuwnkta(voyumzbagz) = ucrydrgket gddwgnpkui (fgmqifblee, dqqrjoeexr - eecqmrddxe)
Not Applicable
137
m-FOLFOXIRI + cetcetuximab
(HMCC)
xplhsmqwle(pkndamxvqe) = bjkmgvzjct koyutdasfn (joiqmxsvbx )
Positive
18 Jan 2024
m-FOLFOXIRI + cetuximab
(LMCC)
xplhsmqwle(pkndamxvqe) = sauoaqjyil koyutdasfn (joiqmxsvbx )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free